A report by QY Research provides an in-depth analysis of the global Molecular Microbiology market, projecting it to grow from $8.427 billion in 2024 to $16.79 billion by 2031 at a 10.5% CAGR. Key players include Roche, Qiagen, Illumina, Abbott, and BioMerieux, with North America leading the market. The market is segmented by product type (Quantitative PCR Detection Diagnostic Kits, Pathogenic Microorganisms Diagnostic Kits), application (Human, Veterinary), and region.

The global Predictive Genetic Testing & Consumer/Wellness Genomics Market was valued at USD 5.74 billion in 2023 and is projected to reach USD 17.66 billion by 2032, growing at a CAGR of 13.33% from 2024–2032. Growth is driven by preventive healthcare adoption, DTC genomic tests, technological advancements in genetic sequencing, and rising chronic disease burdens. Key segments include predictive testing for cancer, cardiovascular diseases, and consumer genomics for wellness optimization.

China's ban on Illumina's DNA sequencing instruments, announced in March 2025 as part of trade retaliation against U.S. tariffs, has created a market vacuum in the genomics sector. PacBio, a U.S. biotech firm specializing in long-read sequencing, has accelerated its partnership with Haorui Gene in Xi’an to expand access to its HiFi technology in China, targeting clinical genomics applications. The move follows Illumina's removal from China's 'Unreliable Entities List' and highlights the growing competition in the sequencing market amid geopolitical tensions.

PacBio has appointed Haorui Gene as an official distributor in China to expand access to its HiFi long-read sequencing technology in clinical and research settings, focusing on transfusion medicine and hematology. Haorui Gene, a leader in blood typing genomics, will distribute PacBio’s Vega platform to support blood centers and genomics institutions in building more complete blood group profiles.

PacBio announced a distribution agreement with Haorui Gene to expand its HiFi sequencing technology in China's clinical diagnostics market. The partnership aims to accelerate adoption of long-read sequencing for precision medicine, with PacBio expecting 16.8% earnings growth in 2025. Haorui Gene, a Chinese leader in blood typing genomics, will leverage its lab network to promote PacBio's technology, supporting national initiatives in HLA typing and rare blood type discovery.